Clinical Trials Directory

Trials / Unknown

UnknownNCT03867695

SERRATHOR TRIAL : Interest of the Novel Serratus Plane Block in Post Operative Analgesia After Video-Assisted Thoracoscopic Lobectomy

SERRATHOR Trial : Analgesic Effect of Serratus Plane Block After Video-Assisted Thoracoscopic Surgery Lobectomy

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
130 (estimated)
Sponsor
University Hospital, Strasbourg, France · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Pain after thoracic surgery remains a challenge for anesthetists. Although VATS for lobectomy is associated with fewer complications compared to thoracotomy, pain after VATS needs to be treated with opioids. Opioids may lead to PONV, respiratory depression, sedation and pruritus. As part of multimodal analgesia and opioids sparing, several local regional techniques has been described: paravertebral block, thoracic epidural analgesia, intercostal block. To date, there is no gold standard for regional anesthesia after VATS. Serratus plane block is a local regional technique, recently described for analgesia after breast surgery and ribs fracture. In our hospital center, since 2016, we used the Serratus plane block for patients scheduled for lobectomy VATS : a local retrospective trial showed that SPB was associated with a lower consumption of morphine. The purpose of this randomized controlled double blinded study is to evaluate the analgesic effect of the Serratus plane block, added to a general anesthesia on post operative pain control after VATS lobectomy.

Conditions

Interventions

TypeNameDescription
DRUGRopivacaineAt the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
DRUGsterile salinePatients will receive a placebo injection with 0,5 mL/kg of sterile normal solution

Timeline

Start date
2019-07-01
Primary completion
2019-07-01
Completion
2020-07-01
First posted
2019-03-08
Last updated
2019-06-04

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03867695. Inclusion in this directory is not an endorsement.